Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonoprazan - Takeda

Drug Profile

Vonoprazan - Takeda

Alternative Names: TAK-438; TAKECAB; VOCINTI; Vocinti; VONOPION®; Vonoprazan fumarate; VONOSAP®; VOQUEZNA; VOQUEZNA DUAL PAK; VOQUEZNA TRIPLE PAK

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Phathom Pharmaceuticals; Takeda
  • Class Amines; Anti-inflammatories; Antibacterials; Antiulcers; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis
  • Phase III Gastrointestinal disorders

Most Recent Events

  • 07 Mar 2024 Phathom plans a phase II trial for Eosinophilic Esophagitis (In adults, In adolescents) in 2024
  • 06 Dec 2023 Phathom Pharmaceuticals plans a phase III trial for Gastro-oesophageal reflux (PO) in USA in 2024
  • 06 Dec 2023 The US FDA accepts NDA for vonoprazan for Gastro-oesophageal reflux for review
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top